BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Dipeptidyl peptidase-4 inhibitors
1
Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes
4/19/2022 3:18:56 AM | Browse: 297 | Download: 544
2
Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials
10/21/2021 8:56:15 AM | Browse: 320 | Download: 448
3
Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence
9/7/2021 8:15:21 AM | Browse: 372 | Download: 396
4
Clinical effects of antidiabetic drugs on psoriasis: The perspective of evidence-based medicine
8/9/2021 10:25:22 AM | Browse: 355 | Download: 570
5
Recent advances in new-onset diabetes mellitus after kidney transplantation
5/6/2021 11:18:51 AM | Browse: 398 | Download: 692
6
Crosstalk between gut microbiota and antidiabetic drug action
3/15/2019 7:18:19 AM | Browse: 860 | Download: 1256
7
Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: A systematic review and meta-analysis of randomized trials
12/24/2015 9:30:00 PM | Browse: 1173 | Download: 1974
8
Incretin manipulation in diabetes management
6/20/2015 5:23:00 PM | Browse: 879 | Download: 1030
9
Incretin-based therapies in prediabetes: Current evidence and future perspectives
12/13/2014 7:02:00 PM | Browse: 1157 | Download: 1542
10
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes
9/1/2014 12:00:00 PM | Browse: 1084 | Download: 902
11
Antidiabetic treatment, stroke severity and outcome
9/1/2014 11:47:00 AM | Browse: 1022 | Download: 895
Write to the Help Desk
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345